Drug Profile

Ketoprofen transdermal - ImprimisRx Pharmaceuticals

Alternative Names: Impracor; Ketotransdel; TDLP-110

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Imprimis Pharmaceuticals
Developer ImprimisRx
Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Acute pain

Most Recent Events

31 Dec 2018 Imprimis Pharmaceuticals changed its name to Harrow Health and added all ophthalmology business to its subsidiary ImprimisRx
28 Mar 2014 Discontinued - Phase-III for Acute pain in USA (Transdermal)
12 Nov 2013 Imprimis withdraws a phase III trial in Acute pain prior to enrolment in USA (NCT01890902)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com